The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...
Investor's Business Daily on MSN15h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
The Centers for Medicare & Medicaid Services (CMS) has added several changes to the Medicare price negotiation process ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback